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Abstract
Background: Despite the increase in the number of people accessing antiretroviral therapy (ART), there is limited
data regarding treatment failure and its related factors among HIV-positive individuals enrolled in HIV care in
resource-poor settings. This review aimed to identify factors associated with antiretroviral treatment failure among
individuals living with HIV on ART in resource-poor settings.
Methods: We conducted a comprehensive search on MEDLINE (PubMed), Excerpta Medica Database (EMBASE),
Cochrane Central Register of Controlled Trials (CENTRAL), World Health Organization’s (WHO’s) library database, and
Latin American and Caribbean Health Sciences Literature (LILACS). We included observational studies (cohort, case-
control, and cross-sectional studies) where adolescents and adults living with HIV were on antiretroviral treatment
regardless of the ART regimen. The primary outcomes of interest were immunological, virological, and clinical
failure. Some of the secondary outcomes were mm3 opportunistic infections, WHO clinical stage, and socio-
demographic factors. We screened titles, abstracts, and the full texts of relevant articles in duplicate. Disagreements
were resolved by consensus. We analyzed the data by doing a meta-analysis to pool the results for each outcome
of interest.
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Results: Antiretroviral failure was nearly 6 times higher among patients who had poor adherence to treatment as
compared to patients with a good treatment adherence (OR = 5.90, 95% CI 3.50, 9.94, moderate strength of
evidence). The likelihood of the treatment failure was almost 5 times higher among patients with CD4 < 200 cells/
mm3 compared to those with CD4 ≥ 200 CD4 cells/mm3 (OR = 4.82, 95% CI 2.44, 9.52, low strength of evidence).
This result shows that poor adherence and CD4 count below < 200 cells/mm3 are significantly associated with
treatment failure among HIV-positive patients on ART in a resource-limited setting.
Conclusion: This review highlights that low CD4 counts and poor adherence to ART were associated to ART
treatment failure. There is a need for healthcare workers and HIV program implementers to focus on patients who
have these characteristics in order to prevent ART treatment failure.
Systematic review registration: The systematic review protocol was registered with the International Prospective
Register of Systematic Reviews (PROSPERO), registration number: 2019 CRD42019136538.
Keywords: HIV, ART, Immunological failure, Virological failure, Clinical failure, Poor outcome
Background
Human immunodeficiency virus (HIV) infections are a
major global public health concern. In 2019, an estimated
38 million people were living with HIV infection (PLWH)
[1]. With new infections, an estimated 1.7 million people
became newly infected with HIV in 2019. Sub-Saharan Af-
rica (SSA) remains the most affected region in the world,
with about 20.7 million prevalent cases and 730,000 new
infections were recorded in 2019, seconded by Asia and
the Pacific region with 5.8 million prevalent cases [1]. Al-
though Southern Africa is home to less than 1% of the
global population, the region has more than a fourth of all
HIV infection in the world, with 300,000 acquired im-
mune deficiency syndrome (AIDS)-related deaths regis-
tered in the same year in SSA [1].
Although anti-retroviral therapy (ART) coverage in
this region has rapidly increased over the past decade
[2]. The greatest gains in access to ART occurred in SSA
[3]. In 2019, only 15 million (73%) PLHIV in the region
were accessing ART, while 3.5 million (60%) in Asia and
the Pacific region [1]. Increasing the use of ART has
contributed to a prominent decline in HIV-associated
morbidity and death/mortality in SSA [2]. United Na-
tions program on HIV/AIDS (UNAIDS) has suggested
universal targets for the year 2020 (90-90-90), which
means diagnosing 90% of all PLHIV who should know
their status (PLHIV), initiating antiretroviral treatment
(ART) for 90% of those diagnosed with HIV infection,
and attaining an undetectable viral load in 90% of those
on ART [4]. Significant progress has been made in
achieving that goal. Globally, PLWH accessing ART has
increased from 21.7 million in 2015 to 25.4 million in
2019, an increase from 45 to 67% of all PLHIV [3, 5].
Antiretroviral treatment failure
Patients with ART failure are increasingly encountered in
resource-limited settings, while recent estimates suggest
only 2% of those currently on ART are on second-line [6],
a far greater number is likely to be failing virologically but
have not switched to an alternative regimen. Furthermore,
an increase in the coverage of ART use among PLHIV,
which has resulted in an increase in the number of indi-
viduals failing first-line ART, and therefore, the magnitude
increases with prolonged use of ART. The WHO pre-
dicted earlier on that 500,000 and 800,000 PLWH on the
first-line combination of ART will require a switch to the
second-line therapy by 2010 [2]. However, the burden of
treatment failure is not well-documented, while there is a
large scale of ARV in resource-limited countries. Meta-
analysis data showed that the rate of the treatment failure
for the first-line was 6.08% globally; however, the study
noted a substantial heterogeneity across regions with
7.10% in Africa and 2.55% in Asia [3].
A retrospective cohort study done in South Africa
found that among patients on non-nucleotide reverse
transcriptase inhibitor (NNRTI)-based ART, after a me-
dian of 15 months on ART treatment, 19% had failed
virologically and immunologically [6]. Studies in East Af-
rica have shown a high prevalence of immunologic fail-
ure ranging from 8 to 57% among clients on the first-
line ART [7–9].
Treatment failure is typically measured in three ways in
poor-resource settings: (i) clinically, as evidenced by disease
progression; (ii) immunologically, as evidenced by trends in
CD4 counts over time; and (iii) virologically, as evidenced by
measurement of HIV RNA levels. In 2013, WHO recom-
mended viral load testing as the preferred monitoring ap-
proach to diagnose and to confirm ARV treatment failure [10].
Factors associated with treatment failure
Earlier studies have emphasized a number of factors that
may be associated with virological suppression in ART;
these are reasons for testing: routine testing, suspected
treatment failure, and repeat testers after suspected failure
[9–11]. While a significant number of studies have found
that treatment failure is significantly associated with young
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age, unsatisfactory adherence, low hemoglobin, history of
lost to follow-up, being male and educational status, and
treatment regimen [12–14], some studies have recognized
low baseline CD4 cell count, rate of CD4 decline, prior ex-
posure to ART and treatment interruptions, and non-
adherence as determinants of treatment failure [15, 16].
In 2016, WHO most recent guideline defined a clinical
failure as a new or recurrent clinical event indicating se-
vere immunodeficiency (WHO clinical stage 4 condition)
after 6 months of effective treatment. Immunological fail-
ure is defined as CD4 count at or below 250 cells/mm3
following a clinical failure or persistent CD4 levels below
100 cells/mm3, and virological failure is defined as viral
load above 1000 copies/mL based on two consecutive viral
load measurements in 3 months, with adherence support
following the first viral load test [17]. The results from a
previous study have confirmed that low baseline CD4 cell
count, particularly < 100 cells/mm3, and history of loss to
follow-up are risk factors for immunological discordance
[18]. Independent risk factors associated with virological
failure were being followed-up at the semirural center,
having experienced unstructured treatment interruptions,
and having low CD4 counts at enrolment [19].
Gender, time on ART, baseline CD4 T cell count, WHO
stage, ART regimen, adherence, and TB co-infection were
associated with viral suppression [20]. The history of the
antiretroviral use before starting ART, change of antiretro-
viral therapy due to toxicity, opportunistic infections while
on ART treatment, level of CD4 + lymphocytes below 100
cells/ml at start of ART, adherence, and clinical stage were
independently associated with virological failure [21]. Age
younger than 40 years was also associated with virologic
failure [22]. The relative contribution of the main predic-
tors to virological failure may differ across settings and
population groups and context. Thus, specific data are
critical to the carrying out of corrective measures.
Importance of the review
Viral load testing provides early and accurate indications
of the treatment failure and the need to switch from the
first-line to second-line drugs, thereby reducing the ac-
cumulation of the drug-resistant mutations and improv-
ing clinical outcomes [23].
However, regular access to routine viral load testing re-
mains a challenge due to the high cost. In such a situation,
clinical and immunological monitoring is used for detecting
treatment failure [24–27]. The number of people accessing
ART has significantly increased in many poor resource set-
tings [28]. Hence, it is significant to sustain treatment suc-
cess and limit the development of treatment failure. For the
timely detection of treatment failure, WHO reconfirmed
the use of viral load testing as the gold standard test to
monitor patients’ response to ART [29]. Where the viral
load is not routinely available, CD4 count and clinical
monitoring should be used to diagnose treatment failure. In
spite of a large number of patients receiving ARTs in low-
and middle-income countries (LMICs) and poor settings,
there are few reports on ART outcomes in these settings.
Identifying baseline predictors of the first-line ART out-
come among PLWH on ART in LMICs where access to
viral load testing is limited is of paramount importance.
The technique and accuracy of identifying treatment
failure in poor settings are important but challenging.
Delayed detection of ART failure may increase drug tox-
icity may lead to the increase of drug resistance related
with mutations (further controlling treatment choices)
and may result in increased morbidity and mortality.
Early detection of treatment failure is crucial to ensure
the effectiveness of the first-line therapy [6].
The main objective of this review was to identify fac-
tors associated with antiretroviral treatment failure
among PLWH on ART in resource-poor settings.
Objective
Primary objective
The primary objective of the study was to determine the
clinical, immunological, and virological factors associ-
ated with antiretroviral treatment failure among PLWH
in resource-poor settings.
Secondary objective
The secondary objective of the study is to identify the
socio-demographic and economic factors associated with
antiretroviral treatment failure among PLWH among
PLWH in resource-poor settings.
Methods
The methods of this systematic review and meta-analysis
were reported as per the Preferred Reporting Items for
Systematic Review and Meta-Analysis Protocols (PRIS
MA-P) checklist [30]. We registered the protocol for this
systematic review on the International Prospective Regis-
ter of Systematic Reviews (PROSPERO) with a registra-
tion number: CRD42019136538.
Criteria for considering studies for review
Types of studies
We included all types of observational studies including
prospective/retrospective or ambi-directional cohort studies,
case-control studies, population-based/nested or hospital-
based case-control studies, and cross-sectional studies.
Interventional studies were excluded from this review.
Types of participants
Adolescents and adults living with HIV who were on
ART for ≥ 6 months, regardless of the regimen. Only
participants with documented baseline CD4 and VL
were considered for this systematic review.
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Type of outcome
Primary outcome
Treatment failure was defined as follows:
Virological failure
Virological failure is defined as a plasma viral load above
1000 copies/ml based on two consecutive viral load mea-
surements after 3 months, with adherence support. A
viral load test is a measurement of the amount of HIV
in a sample of the blood. This is usually reported as the
number of copies per milliliter (copies/mm3) [17].
Immunological failure
Immunological failure is defined as a fall in CD4 count
to the baseline (or below) or persistent CD4 levels below
100 cells/mm3. The CD4 lymphocyte count is an excel-
lent indicator of how healthy the immune system is.
These are a type of white blood cells, called T cells,
which move throughout the human body to find and
destroy bacteria, viruses, and other invading germs. The
CD4 cell count is indicated in cells per mm3, and it is
measured by taking a blood sample [17].
Clinical failure
Clinical failure is defined as the occurrence of new op-
portunistic infections (excluding immune reconstitution
inflammatory syndrome [IRIS]) and/or other clinical evi-
dence of HIV disease progression during therapy. AIDS-
defining illnesses (opportunistic infections) are those
which the Centers for Disease Control and Prevention
(CDC) have classified as being directly associated with
advanced HIV infection. We considered the common
diseases, which are pneumonia, TB, lymphoma, and
cryptococcosis [17].
Secondary outcome
Secondary outcomes for this study are all the predictors’
variables that contribute to treatment failure. The fol-
lowing information was collected if measured at base-
line: CD4 cells (cells/mm3), viral load (copies/ml), WHO
clinical, tuberculosis, opportunistic infection, treatment
regimen (NRTI or NNRTI), BMI, weight, study site
(rural versus urban), gender, age, educational status, em-
ployment status, marital status, and spouse HIV sero-
status.
Inclusion and exclusion criteria
Included studies
Participants in the study were (1) those who had been
on ART for ≥ 6 months and (2) those who had docu-
mented CD4 cell count and viral load measurement at
baseline and 6 months.
Excluded studies
All studies with participants who had pregnancy history
the past 6 months while on treatment and at 6 months’
visit or had missing values of CD4 cell count and viral
load at baseline and 6 months’ visit were excluded.
Search methods for identification of the studies
We conducted a comprehensive search on 5 databases
from December 1, 2000, to November 2019. With assist-
ance from an information specialist, we searched in the
following databases: MEDLINE (Pubmed), EMBASE
(OVID), LILACS (BIREME), Science Citation Index Ex-
panded (SCI-EXPANDED, Web of Science), Social Sci-
ences citation index (SSCI, Web of Science), Conference
Proceedings Citation Index-Social Science & Humanities
(CPCI-SSH, Web of Science), and Cinahl (EBSCOHost).
A detailed search strategy is provided in Appendix 1. A
hand search of citations from selected studies was con-
ducted to identify additional studies missing from the
original electronic searches.
Screening and assessments of study eligibility
All potential studies were imported into Covidence
(Covidence systematic review software, Veritas Health
Innovation, Melbourne, Australia), and two review au-
thors (YL and SJ) independently screened the titles and
abstracts. Both authors also assessed full-text eligibility.
All published full-text articles, abstracts, and brief re-
ports were included, and provided/available complete
data were elicited from them. The disagreements be-
tween the two authors who assessed study eligibility
were resolved by discussion and consensus.
Data extraction, management, and analysis
Data from the full-text articles were extracted by two in-
dependent review authors (YL, SJ) using a standardized
pre-piloted data extraction form. A third reviewer (MK,
PN) checked whether the extracted data were correct.
Extracted data were categorized into four main headings:
general information, socio-demographic and economic
characteristics of participants, and clinical and immuno-
logical information of the participant. In case of missing
information, we clarified the conducted study or the
studies that had relevant data, which were not reported
in the published manuscript, and we contacted the au-
thors for additional information.
Risk of bias and quality of evidence
Two authors independently assessed the risk of bias in
each study by examining the study population, study at-
trition, prognostic factor measurement, outcomes meas-
urement, study confounding, and statistical reporting
(YL and OA). They coded studies as at high, medium,
low, or unclear risk of bias for each of these features
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using the Quality in Prognosis Studies tool (QUIPS tool)
[31]. Finally, we assessed the quality of the evidence
using the Grading of Recommendations Assessment De-
velopment and Evaluations (GRADE) approach using
the five criteria of the GRADE system.
Statistical analysis
For the studies that were relatively homogeneous in terms
of methodology and outcomes, a meta-analysis of the data
was performed. Sufficiently, similar data was pooled using
the inverse variance approach to accommodate crude and
adjusted odds ratios, where possible. Additionally, the
meta-analysis was summarized using pooled estimates, the
95% confidence interval, and the between-study variance
was estimated using Tau2. We extracted all unadjusted
and adjusted measures of the association from all included
studies and converted effect sizes as necessary to possible
selection bias, thus allowing us to use the data from as
many studies as possible. We anticipated that results from
multivariate analyses would have been reported as odds
ratios (ORs), risk ratios (RRs), and hazard ratios (HRs), if
so, we would use ORs as the common measure of the as-
sociation, using RRs and HRs to estimates ORs at a
particular time point [32]. Furthermore, measures of effect
were analyzed using RevMan statistical software for sys-
tematic reviews. Statistical heterogeneity was quantified
using the I2 statistic [33]. If the I2 statistic is high (75 to
100%—as suggested by Higgins et al.) indicating high het-
erogeneity [33], a random effect model was used.
Results
PRISMA flow chart
We retrieved 2418 articles regarding treatment failure
among ART users in poor resource setting as identified
in MEDLINE (PubMed); EMBASE (OVID); LILACS (BI-
REME); Science Citation Index Expanded (SCI-EX-
PANDED, Web of Science), Social Sciences citation
index (SSCI, Web of Science), and Conference Proceed-
ings Citation Index-Social Science & Humanities (CPCI-
SSH, Web of Science), and CINAHL (EBSCOHost).
These are shown in Fig. 1.
Of these initial articles, 3 articles were duplicates; 2158
articles were excluded after reviewing their titles and ab-
stracts and confirmed irrelevant to this review. Thus,
237 potential full-text articles were assessed for eligibil-
ity, which resulted in further exclusion of 100 articles.
Fig. 1 PRISMA flowchart of included studies
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57 had wrong outcomes, 19 assessed HIV drug-resistant
mutations, 12 had the wrong study design, 7 had a
wrong patient population, 2 were not in English 1 and
was a duplicate, 1 had a wrong setting, and 1 was
pediatric population. Finally, 137 studies met the eligibil-
ity criteria. These are shown in Table 1.
Meta-analysis
The association between adherence and treatment fail-
ure was based on six cross-sectional studies [14, 35, 37,
40, 42, 47]. The results as presented in Fig. 2 showed a
strong relationship between treatment failure and poor
treatment adherence. The odds of treatment failure were
nearly 6 times higher among patients who had poor ad-
herence (OR = 5.90, 95% CI 3.50, 9.94, moderate strength
of evidence). The test statistics, however, showed a sub-
stantial heterogeneity (I2 = 65% and p = 0.02).
Similarly, the association between poor adherence and
treatment failure was examined using four cohort studies
[36, 39, 41, 46]. The results as presented in Fig. 3 showed
that the hazard ratio of treatment failure was nearly 2.5
higher among patients who had poor adherence (HR =
Table 1 Characteristics of included studies
References Year of
publication




Babo et al. [34] 2017 Case-control study Ethiopia Adult Stavudine vs. Zidovudine
Nevirapine vs. Efavirenz
307 230











Bisson et al. [37] 2008 Case-control study Botswana Adults older than
18 years
NR 302 247






NRTI and NNRTI 1901 60




Adult EFV, NVP, and other 207 32
Gunda et al. [40] 2019 Case-control study Tanzania Adult AZT/3TC/EFV, AZT/3TC/NVP,
D4T/3TC/NVP, TDF/3TC/EFV
197 24
Haile et al. [41] 2016 Retrospective
cohort study
Ethiopia Adult (≥ 15 years
old)
1a(d4T + 3TC + NVP), 1b(d4T
+ 3TC + EFV),
1c(AZT + 3TC + NVP),
1d(AZT + 3TC + EFV),
1e(TDF + 3TC + EFV), 1f(TDF
+ 3TC + NVP)
4809 113
Hailu et al. [42] 2018 Retrospective
follow-up study
Ethiopia Adults (≥ 20
years)
TDF 3TCEFV/NVP, AZT 3TC
NVP/EFV,
D4T 3TC NVP/EFV, ABC 3TC
EFV
260 30
Hassan et al. [14] 2014 Cross-sectional
study
Kenya Adult Zidovudine-based and
Stavudine-based
232 57
Izudi et al. [43] 2016 Retrospective
cohort
Uganda Adult 383 28
Karade et al. [44] 2016 Cross-sectional
studies
India Adult AZT + 3TC + NVP, AZT +
3TC + EFV
TDF + 3TC + NVP, TDF +
3TC + EFV
d4T + 3TC + NVP/EFV
844 104
Lay et al. [45] 2017 Retrospective
cohort study










Rwanda 15 years and
older
NRTIs, NNRTIs, and PIs 828 70
Ahmed et al. [47] 2019 Case-control study Ethiopia Adult d4t + 3TC + NVP, AZT + 3TC
+ NVP
AZT + 3TC + EFV, TDF + 3TC
+ EFV
TDF + 3TC + NVP
308 199
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2.46, 95% CI 1.72, 3.51, high strength of evidence). The re-
sult of test statistics showed no heterogeneity (I2 = 0% and
p = 0.90). Here too, a random effect meta-analysis model
was used to determine the association with the outcome.
Furthermore, the association between CD4 and treat-
ment failure was examined by using three cross-
sectional studies [35, 40, 47]. The results as presented in
Fig. 4 showed that treatment failure was strongly associ-
ated with CD4 count. The odds of treatment failure were
nearly 5 times higher among patients who had a CD4
cell count of 200 cells/mm3 (OR = 4.82, 95% CI 2.44,
9.52, low strength of evidence). However, the test statis-
tics showed substantial heterogeneity (I2 = 71% and p =
0.03). Hence, a random effect meta-analysis model was
used to determine the association with the outcome.
Likewise, the association between low CD4 count and
treatment failure was also observed using four cohort stud-
ies [36, 38, 45, 46]. Results presented in Fig. 5 showed that
the hazard ratio of treatment failure was nearly 3
times higher among patients who had CD4 lower
than 200 cells/mm3 (HR = 2.98, 95% CI 2.23, 4.00,
moderate strength of evidence). The result of the test
statistics showed no evidence of heterogeneity (I2 =
0% and p = 0.55). A random effect meta-analysis
model was used to determine the association with the
outcome.
Our study also demonstrated similar findings to the
above through data abstracted from two cross-sectional
studies [34, 44]. We also found that treatment failure
was significantly associated with low CD4 count, where
the odds of treatment failure were 1.14 times higher
among patients with CD4 lower than 100 cells/mm3
(OR = 1.14, 95% CI 0.52, 2.47, low strength of evidence).
The test statistics showed moderate heterogeneity (I2 =
49% and p = 0.75), see Fig. 6. Consequently, a random
effect meta-analysis model was computed to determine
the association.
Risk of bias assessment
Most of the studies had a low risk of bias on prognostic
factors that accounted for 125/137, followed by study
participants (123/135), statistical analysis and reporting
(116/137), and outcome measurement (115/137). More-
over, 109/137 studies had a low risk of bias on study
confounding and 103/137 studies had a low risk of bias
on study participant attrition. The full table of results is
shown in Appendix 3: risk of bias assessment.
Discussion
This review was aimed at identifying factors associated
with antiretroviral treatment failure among individuals
living with HIV and showed that low CD4 T cell count
(≤ 200 cells/mm3) and poor adherence to ART were sig-
nificantly associated with virological failure.
In this review, the odds of virological failure were
higher among those who had a CD4 cell count of ≤
Fig. 2 Pooled odds ratio between adherence and treatment failure. Comparison: poor versus good adherence (outcome: virological failure)
Fig. 3 Pooled odds ratio between adherence and treatment failure. Comparison: poor versus good adherence (outcome: virological failure)
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200cells/mm3 in both case-control and cohort studies.
The finding is supported by the studies conducted in
SSA [35, 43], while a retrospective analysis of a large
ART program in Cambodia showed that previous ART
experience, nevirapine-based regimen, and CD4 count ≤
200 cells/mm3 were independently associated with an in-
creased risk of treatment [48]. Similar findings were re-
ported in a meta-analysis data from India, where CD4
count ≤ 200 had a significantly greater risk of treatment
failure [49]. As CD4 cell count increases, viral replication
decreases, which means it has an inverse relationship
with viral load. As patients’ immune status drops, and
the rate of viral load increases compared to the
immuno-competent individuals with HIV infection. In
addition, users with compromised immunity are more
susceptible to different opportunistic infections that en-
dure the cruel cycle of immunity depletion and viral rep-
lication [50].
Moreover, the results found from case-control studies
shown that the odds of virological failure were 6 times
more among those who had poor adherence compared
with those who had good adherence to antiretroviral
treatment. Likewise, the finding from cohort studies
showed that the odds of virological failure were higher
among those who had poor adherence compared with
those who had good adherence to antiretroviral treat-
ment. This finding is supported by findings from pri-
mary studies conducted in African countries [11, 51, 52],
but also consistent with the finding from a study con-
ducted in Vietnam and other developed countries [53–
55]. It is obvious that poor adherence to medication
compromises treatment response due to suboptimal
drug concentration hence creates a conducive environ-
ment for viral replication leading to virological failure
[56, 57]. This reaffirms the need for reinforcement of
drug adherence counseling for HIV patients before and
during their life course of taking ART.
Poor adherence may lead to a number of adverse con-
sequences on both individual and public HIV healthcare
levels. Therefore, the measured efforts are immediately
needed in HIV care by responsive bodies like ART case
managers, adherence counselors in the hospitals on pa-
tients with low current CD4 count through improving
poor adherence to ART treatment by strengthening en-
hanced adherence counseling. Each low-income country
national HIV program should give attention to improv-
ing HIV services to strengthen adherence among pa-
tients on ART in order to reduce the proportion of
patients who are failing the treatment.
Our systematic review has some strengths. We
planned the review a priori with clearly defined selection
criteria. We conducted a comprehensive and exhaustive
search, using many additional sources to identify rele-
vant studies, including reference searches of other HIV/
AIDS conferences (IAS and CROI) for the past 20 years.
This review had several limitations mainly related to
the quality of the evidence available. To our knowledge,
we suspect publication or reporting biases, or both, sug-
gesting that our results may be overestimated. Positive
study bias is likely to be problematic in this review. Our
Fig. 4 Pooled odds ratio between CD4 and treatment failure. Comparison: CD4 < 200 cells/mm3 versus CD4 ≥ 200 cells/mm3 (outcome:
virological failure)
Fig. 5 Pooled odds ratio between CD4 and treatment failure. Comparison: CD4 < 200 versus CD4 ≥ 200 (outcome: virological failure)
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literature search for relevant and potential studies in-
cluded focused searches, i.e., including search terms re-
lated to the “less CD4 count,” “viral load” in our
electronic search. Studies that report a relationship be-
tween the prognostic factors and common outcomes are
therefore more likely to have been identified in these
searches due to reporting of positive results in the study
abstract.
In addition, we also observed that some studies re-
ported positive unadjusted association of factors with
outcomes of interest, but did not report the associ-
ation adjusted for other important covariates. This
may contribute to a likely overestimation of the ad-
justed results. Therefore, future research is required
to investigate the impact and potential strategies to
alleviate reporting and publication bias, as well as ini-
tiatives to require registration of protocols and publi-
cation of prognostic studies.
Furthermore, our review was the pooling of the ad-
justed the results despite studies did not include identi-
cal sets of covariates. Studies included in this review
were homogenous; therefore, pooling of the adjusted re-
sults was feasible. However, comparison and interpret-
ation may be challenging in this case. Our review only
focused on studies conducted in poor resource settings
limiting its generalizability to high-income settings.
Strength of evidence
The strength of evidence contributing to several outcomes
in this review was graded as low, moderate, or high. We
used the GRADE approach to assess the strength of evi-
dence as shown in the summary of the finding table, Ap-
pendix 4. The certainty of evidence was downgraded in
most instances due to a high risk of bias as well as
inconsistency.
Conclusion
ART failure among individuals living with HIV is a pub-
lic health concern; the timing and accuracy of identifying
treatment failure in resource-limited settings are funda-
mental but challenging. The findings of this review
highlighted that low CD4 counts and poor adherence to
ART were associated to ART treatment failure. There is
an urgent need that health professionals and HIV pro-
grams should focus on novel approaches for patients
who have these characteristics in order to prevent ART
failure. Further review is required to be done in multiple
ART centers and a broader community as well as the
different factors associated with treatment failure to de-
cide whether there are discrepancies in virological and
immunological responses to antiretroviral therapy at dif-
ferent stages of HIV infection.
Appendix 1
Search strategy—database
#1 Search ((HIV OR hiv-1 OR hiv-2* OR hiv1 OR hiv2
OR hiv infect* OR human immunodeficiency virus OR
human immune deficiency virus OR human immuno-
deficiency virus OR human immune-deficiency virus OR
((human immun*) AND (deficiency virus)) OR acquired
immune deficiency syndromes
OR acquired immune deficiency syndrome OR ac-
quired immuno-deficiency syndrome OR
acquired immune-deficiency syndrome OR ((acquired
immun*) AND (deficiency syndrome)) OR HIV/AIDS))
#2 Search ((HIV infections [MeSH] OR HIV [MeSH]))
#3 Search (#1 OR #2)
#4 Search ((Antiretroviral* OR ((anti) AND (retro-
viral*)) OR ARV* OR ART OR “antiretroviral therapy”
OR HAART OR ((highly) AND (active) AND (anti-
retroviral*) AND (therap*)) OR ((anti) AND (hiv)) OR
((anti) AND (acquired immunodeficiency)) OR ((anti)
AND (acquired immuno-deficiency)) OR ((anti)
AND (acquired immune-deficiency)) OR ((anti) AND
(acquired immun*) AND (deficienc*))))
#5 Search ((antiretroviral agents [Mesh] OR antiretro-
viral therapy, highly active [Mesh]))
#6 Search (#4 OR #5)
#7 search #3 AND #6
#8 Search (virological failure OR Immunological fail-
ure OR less CD4 count OR viral load)
#9 Search (low-income setting OR disadvantaged com-
munities OR resource limited setting OR Sub-Saharan
Africa)
#10 Search (#7 AND #8 AND #9)
Fig. 6 Pooled odds ratio between CD4 and treatment failure. Comparison: CD4 < 100 versus CD4 ≥ 100. (outcome: virological failure)
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Appendix 3
Risk of bias assessment
Table 2 Risk of bias assessment




participant Attrition Factor measurement Outcome measurement Study confounding
1 Abah 2018 Low High Low Low Low Low
2 Ahmed 2019 Low Low Low Low Low Low
3 Ahn 2019 Low High Low Low Low Low
4 Ahoua 2009 Low Low Low Low Low Low
5 Assefa 2014 Low High Low Low Low Low
6 Ayalew 2016 Low Low Low Low Low Low
7 Ayele 2018 Low Low Low Low Low Low
8 Babo 2017 Low Low Low Low Low Low
9 Bayou 2015 Low High Low Low Low Low
10 Bayu 2017 Low Low Low Low Low Low
11 Billioux 2015 Low Low High High Low Low
12 Biscione 2014 Low Low High High High Low
13 Bisson 2008 Low Low High Low High Low
14 Boender 2016a Low Low Low Low Low Low
15 Boender 2016b Low Low Low Low Low Low
16 Boettiger 2016c Low Low Low Low Low Low
17 Boettiger 2015 Low Low Low Low Low Low
18 Boettiger 2016d Low Low Low Low Low Low
19 Boettiger 2014 Low Low Low Low Low Low
20 Boulle 2015 Low Low Low Low Low Low
21 Braun 2017 Low Low Low Low High High
22 Brooks 2016 Low Low Low Low High High
23 Bulage 2017 Low High Low Low Low Low
24 Byabene 2017 Low Low Low Low Low Low
25 Cao 2018 Low Low Low Low Low Low
26 Carriquiry 201 Low Low Low Low Low Low
27 Caseiro 2018 Low Low Low High High Low
28 Castelnuovo 2016 Low Low Low Low Low Low
29 Cesar 2015 Low Low Low Low Low Low
30 Cesar 2014 Low Low Low Low Low Low
31 Chaiwarith 2011 Low Low Low Low Low Low
32 Chaiwarith 2007 Low Low High Low Unclear Low
33 Chakravarty 2015 Low Low Low Low Unclear Low
34 Charles 2013 Low Unclear Low Low Unclear Low
35 Chawana 2014 Low Low Low Low Unclear Low
36 Chen 2014 Low High Low Low High Low
37 Chhim 2018 Low High Low Low Low Low
38 Chkhartishvili 2014 Low Low Low Low Unclear Low
39 Collier 2017 Low Low Low Low Low Low
40 Costiniuk 2014 High Unclear Low Low High High
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Table 2 Risk of bias assessment (Continued)




participant Attrition Factor measurement Outcome measurement Study confounding
41 Court 2014 Low Low Low Low Low Low
42 Datay 2010 Low Low Low Low Unclear Low
43 DeBoni 2018 Low Low Low Low Low Low
44 deLaHoz 2014 Low Low Unclear Unclear Unclear Low
45 Dolling 2017 Low Low Low Low Low Low
46 Dray-Spira 2007 Low Low Low Low Unclear Low
47 Ekstrand 2011 Low Low High Unclear Unclear High
48 Rusine 2013 Low Low Low Low Low Low
49 Sadashiv 2017 Low Low Low Low Low Low
50 Safren 2014 Low Low Low Low Low Low
51 Saracino 2014 Low Low Low Low Low Low
52 Singini 2016 Low Low Low Low Low Low
53 Sithole 2018 Low Low Low Low Low Low
54 Sovershaeva 2019 Low Low Low Low Low Low
55 Syed 2016 Low Low Low Low Low Low
56 Telele 2018 Low Low Low Low Low Low
57 Teshome 2014 Low Low Low Low Low Low
58 Thiha 2016 High Low Low Low Low Low
59 Tran 2014 Low High Low Low Low Low
60 Tsegaye 2016 Low High Low Low Low Low
61 vandenBerg 2005 Low Low Low Low Low Low
62 Vanobberghen 2015 Low Low Low Low Low Low
63 Wang 2011 High High Low Low Low Low
64 Yimer 2015 Low Low Low Low Low Low
65 Yirdaw 2015 Low Low Low Low Low Low
66 Zhao 2017 Low High Low Low Low Low
67 Zoufaly 2015 Low Low Low Low Low Low
68 Elema 2009 Low Low Unclear low Unclear Low
69 Enderis 2009 Low Low Low Low Low Low
70 Eshleman 2017 Low Low Low Low Low Low
71 Evans 2018 Low High Low Low Low Low
72 Evans 2013 Low High Low Low Low Low
73 Fatti 2019 Low Low Low Low Low Low
74 Fatti 2014 Low Low Low Low Low Low
75 Ferradini 2007 Low Low Low Low Low Low
76 Ferreyra 2012 Low Low Low Low Low Low
77 Fibriani 2013 Low Low Low Unclear Unclear Low
78 Flynn 2017 Low Low Low Low Low Low
79 Fogel 2017 unclear Unclear Low Low Low Unclear
80 Ford 2010 Low Low Low Low Low Low
81 Fox 2012 Low Low Low Low Low Low
82 Fox 2010 Low Low Low Low Low Low
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Table 2 Risk of bias assessment (Continued)




participant Attrition Factor measurement Outcome measurement Study confounding
83 Goldman 2008 Low Low Low Low Unclear Low
84 Gross 2017 Low Low Low Low Low Low
85 Gunda 2019 Low Low Low Low Low Low
86 Haggblom 2016 Low Low Low Low Low Low
87 Haile 2016 Low High Low Low High Low
88 Hailu 2018 Low Low Low Low Low Low
89 Hamers 2012 Low Low Low Low Low Low
90 Hare 2014 Low Low Low Low Low Low
91 Hassan 2014 Low Low Low Low Low Low
92 Hawkins 2015 Low High Low Low Low Low
93 Hawkins 2016 Low Low Low Low Low Low
94 Hermans 2018 Low High Unclear Low Unclear Low
95 Huang 2015 Low High Low Low Low Low
96 Hunt 2017 Low Low Low High Unclear Low
97 Huong 2011 Low Low Low low Unclear Low
98 Inzaule 2018 Low Low Unclear low Low Low
99 Izudi 2016 Low Low Unclear low Low Low
100 Jiamsakul 2016 Low High Low low Low Low
101 John 2016 Low Low Low low Low Low
102 Joram 2017 Low High Low High Low Low
103 JosephDavey 2018 Low Low Low low Low Low
104 Kamya 2007 Low Low Unclear low Low Low
105 Kan 2017 Low Low Low High Low Low
106 Karade 2016 Low Low Low High Low Low
107 Kazooba 2018 Low High Low Low Low Low
108 Khienprasit 2011 Low Low Low High Low High
109 Kyaw 2017 Low High Low High Low Low
110 Lay 2017 Low Low Low High Low High
111 Leng 2014 Low Low High High Low Low
112 Lenjisa 2015 Low High Low Low Low High
113 Levison 2011 Low Low Low Low High High
114 Liegeois 2013 Low Low Low High Low High
115 Masikini 2019 High Low Low High Low Low
116 Meloni 2016 Low Low Low High High Low
117 Mpawa 2017 High High Low High Low High
118 Mujugira 2016 Low Low Low low Low Low
119 Mungwira 2018 Low High Low High Low Low
120 Musa 2015 Low Low Low Low Low Low
121 Nachega 2008 High Low Low Low High Low
122 Ndahimana 2016 High Low Low Low Low High
123 Negi 2018 Low High Low Low Low HIgh
124 Nsanzimana 2019 High High Low Low Low High
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Appendix 2
Risk of bias criteria and justifications
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b. Description of the source
population or population of
interest
c. Description of the baseline
study sample
d. Adequate description of
the sampling frame and
recruitment.
Risk of bias criteria and justifications (Continued)
the PF and outcome is
unlikely to be different for
participants and eligible
nonparticipants
e. Adequate description of
the period and place of
recruitment





The study data available
(i.e., participants not lost to
follow-up) adequately rep-
resent the study sample
Summary
a. Adequate response rate
for study participants (> 80%)
High bias: The
relationship between the
PF and outcome is very





between the PF and





PF and outcome is








c. Reasons for loss to follow-
up are provided
d. Adequate description of
participants lost to follow-up
e. There are no important
differences between
participants who completed




The PF is measured in a
similar way for all
participants
Summary
a. A clear definition or
description of the PF is
provided
High bias: The
measurement of the PF is
very likely to be different
for different levels of the
outcome of
interestModerate bias:
b. Method of PF
measurement is adequately
valid and reliable (i.e., direct
Table 2 Risk of bias assessment (Continued)




participant Attrition Factor measurement Outcome measurement Study confounding
125 Ntamatungiro 2017 Low High Low Low Low High
126 Ongubo 2017 High High Low Low Low High
127 Onoya 2016 Low High Low Low Low Low
128 Palladino 2013 High Low Low Low Low Low
129 Patrikar 2017 Low Low Low High Low High
130 Penot 2014 High Low Low High Low High
131 Raimondo 2017 Low Low Low low Low Low
132 Rajasekaran 2007 Low Low Low High High Low
133 Ramadhani 2007 High Low Low low Low High
134 Rangarajan 2016 Low High Low low Low Low
135 Rohr 2016 Low High Low low Unclear Low
136 Ruperez 2014 High Low Low low Low High
137 Ruperez 2015 High Low Low low Low High
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Risk of bias criteria and justifications (Continued)
The measurement of the
PF may be different for
different levels of the
outcome of interestLow
bias: The measurement of
the PF is unlikely to be
different for different




c. Continuous variables are
reported or appropriate cut-
points are used
d. The method and setting
of measurement of PF is the
same for all study
participants
e. Adequate proportion of
the study sample has
complete data for the PF (>
80%)
f. Appropriate methods of




The outcome of interest is
measured in a similar way
for all participants
Summary
a. A clear definition of the
outcome of interest is




outcome is very likely to
be differently related to




differently related to the
baseline level of the
PFLow bias: The
measurement of the
outcome is unlikely to be
differently related to the
baseline level of the PF
b. Method of outcome
measurement used is




c. The method and setting of
outcome measurement is










High bias: The observed
effect of the PF on the
outcome is very likely to
be distorted by another
factor related to PF and
outcomeModerate bias:
The observed effect of the
PF on outcome may be
distorted by another
factor related to PF and
outcomeLow bias: The
observed effect of the PF
on the outcome is
unlikely to be distorted by
another factor related to
PF and outcome
b. Clear definitions of the
important confounders
measured are provided
c. Measurement of all
important confounders is
adequately valid and reliable
d. The method and setting
of confounding
measurement are the same
for all study participants
e. Appropriate methods are




for in the study design (by
limiting the study to specific




for in the analysis (by






The statistical analysis is
appropriate, and all primary
outcomes are reported
Summary
a. Sufficient presentation of
data to assess the adequacy
of the analytic strategy
High bias: The reported
results are very likely to
be spurious or biased
related to analysis or
reportingModerate bias:
The reported results may
be spurious or biased
related to analysis or
reportingLow bias: The
reported results are
unlikely to be spurious or
biased related to analysis
or reporting
b. Strategy for model
building is appropriate and is
based on a conceptual
framework or model
c. The selected statistical
model is adequate for the
design of the study
d. There is no selective
reporting of results (based on
the study protocol, if available,
or on the “Methods” section)
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